Ceramide-based risk score: A novel laboratory tool for cardiovascular risk stratification in hyperuricemia and gout

Gout and hyperuricemia increase cardiovascular disease risk, highlighting the need for improved risk stratification. In this pilot study, we evaluated the Coronary Event Risk Test (CERT) in 94 hyperuricemic and 196 gout patients, and 53 controls. Plasma ceramides were determined by liquid chromatogr...

Full description

Saved in:
Bibliographic Details
Published inVascular pharmacology Vol. 159; p. 107495
Main Authors Kvasnička, Aleš, Friedecký, David, Piskláková, Barbora, Rozhon, Jakub, Pavelka, Karel, Stibůrková, Blanka
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2025
Subjects
Adult
Aged
Biomarkers - blood
Cardiovascular
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
Cardiovascular risk
Case-Control Studies
Ceramides
Ceramides - blood
Chromatography, Liquid
Coronary event risk test
Decision Support Techniques
Female
Gout
Gout - blood
Gout - complications
Gout - diagnosis
Heart Disease Risk Factors
Humans
Hyperuricemia
Hyperuricemia - blood
Hyperuricemia - complications
Hyperuricemia - diagnosis
Lipidomics
Male
Middle Aged
Pilot Projects
Predictive Value of Tests
Prognosis
Risk Assessment
Uric Acid - blood
Ceramides
Coronary event risk test
Lipidomics
Hyperuricemia
Gout
Cardiovascular risk
Online AccessGet full text
ISSN1537-1891
1879-3649
1879-3649
DOI10.1016/j.vph.2025.107495

Cover

More Information
Summary:Gout and hyperuricemia increase cardiovascular disease risk, highlighting the need for improved risk stratification. In this pilot study, we evaluated the Coronary Event Risk Test (CERT) in 94 hyperuricemic and 196 gout patients, and 53 controls. Plasma ceramides were determined by liquid chromatography–mass spectrometry. Elevated CERT scores (≥7) occurred in 11.7 % (2-fold increase) of hyperuricemic and 31.12 % (5.5-fold increase) of gout patients compared to controls. Additionally, both hyperuricemic and gout patients with increased CERT also exhibited higher levels of inflammation and atherogenic index of plasma, both of which were significantly associated with CERT. Incorporating CERT into routine care may enhance risk stratification and guide targeted interventions in this patient population. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1537-1891
1879-3649
1879-3649
DOI:10.1016/j.vph.2025.107495